Abstract:IMPORTANCE: Current methods for glioma treatment response assessment are limited. Intracranial cerebrospinal fluid (CSF) may provide a previously untapped source of longitudinal biomarkers, such as cell-free DNA (cfDNA), for disease monitoring. OBJECTIVE: To assess the feasibility of obtaining longitudinal intracranial CSF cfDNA from patients with gliomas during their disease course. DESIGN: This case series was initiated in 2021, with patients followed until last clinical follow-up (death or present time). SETTING: This single-center study was conducted at a large academic medical center. PARTICIPANTS: Adults with gliomas were recruited for longitudinal intracranial CSF collection using 1) Ommaya reservoirs, from which CSF would be sampled on at least two separate occasions, or 2) CSF collection from other clinically indicated CSF access devices, such as ventriculoperitoneal (VP) shunts. INTERVENTIONS: CSF was collected from Ommaya reservoirs in four patients and from an existing VP shunt in one patient. MAIN OUTCOMES AND MEASURES: The study aimed to collect CSF for biobanking and biomarker discovery, with the hypothesis that CSF could serve as a source of longitudinally acquirable biomarkers. RESULTS: Five patients (2 females, 3 males; median: 40 years, range 32-64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n=4/5 patients) or VP shunt (n=1/5). Three patients had glioblastoma and two had astrocytoma, IDH-mutant, grade 4. In total, thirty-five CSF samples were obtained (median: 3.80 mL; 0.5-5 mL), with 30 (85.7%) yielding sufficient cfDNA for Next-Generation Sequencing (n=28) or Low-Pass Whole Genome sequencing (all samples). Tumor fraction was found to increase with radiographic progression. Changes in variant allelic frequencies (VAFs) may be seen within individual patients after resection and chemoradiation. In two patients, changes in tumor-specific IDH1 VAF correlated with CSF D-2-hydroxyglutarate levels, the oncometabolite of IDH mutant tumors. Copy number burden (CNB) decreased below the limit of quantification during treatment. CONCLUSIONS AND RELEVANCE: Longitudinal CSF cfDNA can feasibly be obtained via CSF access devices in patients with gliomas during their disease course. Ongoing studies will evaluate hypotheses generated in this case series regarding how longitudinal CSF cfDNA could be utilized to sensitively detect changes in disease burden. Trial Registration: [NCT04692324][1] https://clinicaltrials.gov/study/[NCT04692324][1]; [NCT04692337][2] https://clinicaltrials.gov/study/[NCT04692337][2]### Competing Interest StatementXiaoxi Dong, Chao Dai, Wei Mo, Pan Du, and Shidong Jia report employment at Predicine, Inc. Wei Mo, Pan Du, and Shidong Jia also report stock and other ownership interests in Predicine, Inc.### Clinical TrialNCT04692337### Funding StatementCRC was supported by the National Institute of Health T32GM145408. AMC was supported by NIH T32GM00868. TCB, TJK, SHK, and JEP were supported by NINDS R61 NS122096. TCB was supported by the Mayo Clinic Center for Individualized Medicine and CCaTS award UL1TR002377, the American Brain Tumor Association, Brains Together for the Cure, Humor to fight the Tumor, and Lucius & Terrie McKelvey. ### Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Mayo Clinic Institutional Review Board and all participants provided their consent to participate in this study. This study was performed in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon request to the author. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04692324&atom=%2Fmedrxiv%2Fearly%2F2024%2F02%2F24%2F2024.02.21.24303164.atom [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04692337&atom=%2Fmedrxiv%2Fearly%2F2024%2F02%2F24%2F2024.02.21.24303164.atom

Angi-12. The Impact Of Standard-Of-Care Treatment On The Relationship Between Cell Density And Sox2 Positivity In Glioblastoma Patients At Autopsy

Angi-11. Sex Differences In Sox2 Glioblastoma Expression Outside Mri-Defined Contrast Enhancement At Autopsy

TMIC-82. SPATIAL AND SINGLE-CELL PROTEOMIC LANDSCAPING OF THE HYPOXIC MICROENVIRONMENT IN GLIOBLASTOMA

293 The Impact of Tumor Mutational Status on Protoporphyrin IX Accumulation in Tumor-Associated Macrophages in Glioblastoma Patients

Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma

384 BOLD Asynchrony Reveals Tumor Burden in IDH-Wildtype Gliomas

Prognostic value of stem cell markers in glioblastoma

Pre‐operative mean platelet volume is associated with overall survival in patients with IDH‐wildtype glioblastoma undergoing maximal safe resection

Stem Cell Associated Gene Expression in Glioblastoma Multiforme: Relationship to Survival and the Subventricular Zone

Sex-Specific Differences in Patients with IDH1-Wild-Type Grade 4 Glioma in the ReSPOND Consortium

Epco-34. Deciphering The Longitudinal Trajectories Of Glioblastoma By Integrative Single-Cell Genomics

IDH1, ATRX, p53, and Ki67 Expression in Glioblastoma patients: Their Clinical and Prognostic Significance—A Prospective Study

Biom-63. Long-Term Survival And Molecular Characterization Of Idh-Wildtype Glioblastoma In An Asian Cohort

Nimg-59. Comparative Analysis Of Long-Term Glioblastoma Survivors Using Machine Learning Generated Radio-Pathomic Metrics

Glioma Monitoring Via Longitudinal Intracranial Cerebrospinal Fluid Cell-Free DNA.

Immunophenotypic Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A Cohort Study

Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results.

RBIO-03. HETEROGENEITY OF HUMAN PATIENT-DERIVED XENOGRAFTS GROWTH RATES RESPONSES TO THE RADIATED MICROENVIRONMENT

Gene Expression Patterns Associated with Survival in Glioblastoma

Molecular Characterization and Survival Analysis of a Cohort of Glioblastoma, IDH-wildtype

Single-Cell Molecular Characterization to Partition the Human Glioblastoma Tumor Microenvironment Genetic Background